Brivaracetam

Brivaracetam
Clinical data
Pronunciation	/ˌbrɪvəˈræsətəm/ BRIV-ə-RASS-ə-təm
Trade names	Briviact, Nubriveo, Brivajoy
AHFS/Drugs.com	Monograph
MedlinePlus	a616027
License data	US DailyMed: Brivaracetam;
Pregnancy; category	AU: B3;
Routes of; administration	By mouth, intravenous
ATC code	N03AX23 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); CA: ℞-only; US: Schedule V; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	Nearly 100%
Protein binding	≤20%
Metabolism	Hydrolysis by amidase, CYP2C19-mediated hydroxylation
Metabolites	3 inactive metabolites
Elimination half-life	≈9 hours
Excretion	Kidneys (>95%)
Identifiers
	IUPAC name (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide;
CAS Number	357336-20-0 [chemspider];
PubChem CID	9837243;
DrugBank	DB05541;
ChemSpider	8012964 ;
UNII	U863JGG2IA;
KEGG	D08879;
ChEBI	CHEBI:133013 ;
ChEMBL	ChEMBL607400 ;
CompTox Dashboard (EPA)	DTXSID00905081 ;
ECHA InfoCard	100.118.642
Chemical and physical data
Formula	C11H20N2O2
Molar mass	212.293 g·mol−1
3D model (JSmol)	Interactive image;
Specific rotation	[α]D −60°
Melting point	72 to 77 °C (162 to 171 °F)
	SMILES O=C(N)[C@@H](N1C(=O)C[C@@H](CCC)C1)CC;
	InChI InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1 ; Key:MSYKRHVOOPPJKU-BDAKNGLRSA-N ;

Brivaracetam, sold under the brand name Briviact among others, is a chemical analog of levetiracetam, a racetam derivative with anticonvulsant (antiepileptic) properties. It has been approved since 2016. It is marketed by the pharmaceutical company UCB. It is used to treat partial-onset seizures with or without secondary generalisation, in combination with other antiepileptic drugs.